<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="46455">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02501473</url>
  </required_header>
  <id_info>
    <org_study_id>IMDZ-G142</org_study_id>
    <nct_id>NCT02501473</nct_id>
  </id_info>
  <brief_title>Study of Intratumoral G100 With Or Without Pembrolizumab In Patients With Follicular Non-Hodgkin's Lymphoma</brief_title>
  <official_title>Phase 1/2 Study of Intratumoral G100 With Or Without Pembrolizumab In Patients With Follicular Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immune Design</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Immune Design</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1/2 open label trial of G100 in patients with low grade NHL. G100 is
      composed of glucopranosyl lipid A in a stable emulsion and is a potent TLR4 (toll-like
      receptor-4) agonist. G100 will be administered by direct injection (intratumorally) into
      tumors of low grade NHL following standard low dose radiation therapy. Preclinical models
      and clinical studies in other cancers such as Merkel cell carcinoma have demonstrated that
      G100 administered in this manner can alter the tumor microenvironment, activate dendritic
      cells, T cells and other immune cells and induce systemic anti-tumor immune responses. In
      this trial, the safety, immunogenicity, and clinical efficacy of G100 will be examined alone
      or with pembrolizumab.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center Phase 1/2 open label trial of intratumoral G100 in patients with low
      grade NHL. Patients with NHL who are to be treated with local radiation will be enrolled and
      receive G100 to an accessable tumor mass. Clinical response will be evaluated in the
      injected lesion and systemic (abscopal) responses will be evaluated in distal areas involved
      with tumor.

      The study will be conducted in 3 parts. In Part 1, Dose Escalation, 2 sequentially enrolled
      cohorts of patients will be treated at one of 2 dose levels of G100 using a standard
      escalation design. In this portion of the study, both follicular and marginal zone NHL will
      eligible. In Part 2, 2 groups of patients with follicular NHL may be examined. One group
      will be randomly assigned to receive either single agent G100 intratumorally at the maximum
      safe dose determined in Part 1 following local radiation or will receive the same treatment
      regimen sequentially administered with pembrolizumab. A second treatment group may be
      explored if the safety profile in Part 1 is acceptable. In this optional group, patients
      with injectable tumors of 4 cm or greater would be enrolled and treated with a higher dose
      of G100. In Part 3, G100 Expansion of higher dose in patients with follicular NHL will be
      enrolled to receive local radiation therapy and intratumoral G100.

      The primary goal of this study is to determine the safety and tolerability of different
      doses of G100 when administered by intratumoral injection. The development of anti-tumor
      immune responses and preliminary evidence of clinical responses in local and distal tumor
      sites will also be examined.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability by assessing the frequency and severity of adverse events</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>To evaluate the safety and tolerability of ascending doses of intratumoral G100 in patients with follicular NHL receiving local radiation by assessing the frequency and severity of adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Response Assessment as a preliminary indication of efficacy</measure>
    <time_frame>Day 1 to Progression (estimated 24 + months)</time_frame>
    <description>Assess clinical responses at local and distal sites of disease as a preliminary indication of efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abscopal tumor response in non-treated, distal tumor sites</measure>
    <time_frame>Screening to End of Study Visit (expected average is 24 Months)</time_frame>
    <description>To assess abscopal tumor responses in non-treated, distal tumor sites</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory Biomarkers of immunologic and tumor response</measure>
    <time_frame>Screening to End of Study Visit (expected average is 24 Months)</time_frame>
    <description>Assess blood and tumor samples for exploratory biomarkers of immunologic and tumor response</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Follicular Lymphoma (Marginal Zone Allowed During Dose Escalation Only)</condition>
  <arm_group>
    <arm_group_label>Part 1: Dose Escalation Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intratumoral injections of G100 at 5μg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Dose Escalation Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>or Intratumoral injections of G100 at 10μg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Patient Expansion G100 and Pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intratumoral injections G100 or sequential intratumoral G100 and pembrolizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Large Tumor (Optional)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intratumoral injections G100 at 20 μg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3: Expansion of Dose Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Expansion of 20 μg Dose Group with follicular NHL will receive local radiation therapy and intratumoral G100 at 20 µg/dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G100</intervention_name>
    <description>GLA is a fully synthetic toll-like receptor-4 (TLR4) agonist</description>
    <arm_group_label>Part 1: Dose Escalation Cohort 1</arm_group_label>
    <arm_group_label>Part 1: Dose Escalation Cohort 2</arm_group_label>
    <arm_group_label>Part 2: Patient Expansion G100 and Pembrolizumab</arm_group_label>
    <arm_group_label>Part 2: Large Tumor (Optional)</arm_group_label>
    <arm_group_label>Part 3: Expansion of Dose Group</arm_group_label>
    <other_name>glucopyranosyl lipid A stable emulsion, GLA-SE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>PD-1 Inhibitor</description>
    <arm_group_label>Part 2: Patient Expansion G100 and Pembrolizumab</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Follicular low-grade NHL: either treatment naïve or relapsed or refractory following
             at least one prior treatment. In Part 1 Dose Escalation only, in addition to
             follicular NHL, marginal zone B cell lymphomas: either treatment naïve or relapsed or
             refractory following at least one prior treatment.

          2. Tumor mass(es) accessible for intratumoral injection and are being considered for
             local radiation therapy and at least one additional site of disease outside the
             radiation field for assessment of distal (abscopal) response

          3. ≥ 18 years of age

          4. Life expectancy of ≥ 6 months per the investigator

          5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          6. ECG without evidence of clinically significant arrhythmia or ischemia

          7. If female of childbearing potential (FCBP), willing to undergo pregnancy testing and
             agrees to use two methods of birth control or is considered highly unlikely to
             conceive during the dosing period and for three months after last study treatment, or
             if receiving pembrolizumab, four months after last treatment

          8. If male and sexually active with a FCBP, must agree to use highly effective
             contraception such as latex condom or is sterile (e.g. following a surgical
             procedure) during the dosing period and for three months after last study treatment,
             or if receiving pembrolizumab, four months after last treatment

        Exclusion Criteria:

          1. Cancer therapies, including chemotherapy, radiation (non-study regimen related),
             biologics or kinase inhibitors, G-CSF or GM-CSF within 4 weeks prior to the first
             scheduled G100 dose

          2. Investigational therapy within 4 weeks prior to G100 dosing

          3. Prior administration of other intratumoral immunotherapeutics

          4. Inadequate organ function including:

               1. Marrow: Peripheral blood leukocyte count (WBC) &lt; 3000/mm3, absolute neutrophil
                  count ≤ 1500/mm3, platelets &lt; 75000/mm3, or hemoglobin &lt; 10 gm/dL

               2. Hepatic: alanine aminotransferase (ALT), and aspartate aminotransferase (AST) &gt;
                  2.5 x Upper Limit of Normal (ULN), total serum bilirubin &gt; 1.5 x ULN (patients
                  with Gilbert's Disease may be included if their total bilirubin is ≤3.0 mg/dL)

               3. Renal: Creatinine &gt; 1.5x ULN

               4. Other: INR (prothrombin time ratio) or partial thromboplastin time (PTT) &gt;1.5 x
                  ULN

          5. Significant immunosuppression from:

               1. Concurrent, recent (≤ 4 weeks ago) or anticipated treatment with systemic
                  corticosteroids at any dose, or

               2. Other immunosuppressive medications such as methotrexate, cyclosporine,
                  azathioprine or conditions such as common variable hypogammaglobulinemia

          6. Pregnant or nursing

          7. Myocardial infarction within 6 months of study initiation, active cardiac ischemia or
             New York Heart Association (NYHA) Grade III or IV heart failure

          8. History of other cancer within 2 years (except non-melanoma cutaneous malignancies
             and cervical carcinoma in situ)

          9. Recent (&lt; 1 week ago) clinically significant infection, active tuberculosis or
             evidence of active hepatitis B, hepatitis C or HIV infection

         10. Central nervous system involvement with lymphoma, including parenchymal and
             leptomeningeal disease

         11. Significant autoimmune disease, including active non-infectious pneumonitis, with the
             exception of alopecia, vitiligo, hypothyroidism or other conditions that have never
             been clinically active or were transient and have completely resolved and require no
             ongoing therapy

         12. Psychiatric, other medical illness or other condition that in the opinion of the PI
             prevents compliance with study procedures or ability to provide valid informed
             consent

         13. History of significant adverse or allergic reaction to any component of G100 and, if
             enrolled in Part 2, anti-PD1 antibodies.

         14. Use of anti-coagulant agents or history a significant bleeding diathesis. (If a
             superficial lymph node or subcutaneous mass is to be injected, patients on agents
             such as non-steroidal anti-inflammatory drugs (NSAIDs), aspirin, or clopidogrel are
             eligible and these agents do not have to be withheld. For procedures with moderate or
             significant risk of bleeding, long-acting agents such as aspirin or clopidogrel
             should be discussed with the Medical Monitor and may need to be discontinued before
             G100 therapy.

             For patients enrolled in Part 2 with the potential to receive pembrolizumab:

         15. History of interstitial lung disease

         16. Received a live virus vaccine within 30 days of planned study start

         17. Has undergone prior allogeneic hematopoietic stem cell transplantation within the
             last 5 years. (Subjects who have had a transplant greater than 5 years ago are
             eligible as long as there are no symptoms of GVHD.)

         18. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or if
             the patient has previously participated in Merck MK-3475 clinical trials.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Immune Design</last_name>
    <phone>650-392-8312</phone>
    <email>clinicaltrials@immunedesign.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Kyung</last_name>
      <phone>626-256-4673</phone>
      <phone_ext>80247</phone_ext>
      <email>ckyung@coh.org</email>
    </contact>
    <contact_backup>
      <last_name>Meghan Bharadwaj</last_name>
      <phone>626-256-4673</phone>
      <phone_ext>80407</phone_ext>
      <email>Mbharadwaj@coh.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erika Cavallone</last_name>
      <phone>415-476-4765</phone>
      <email>erika.cavallone@ucsf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yale Comprehensive Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Benson, MS</last_name>
      <phone>203-985-9876</phone>
      <email>jennifer.benson@yale.edu</email>
    </contact>
    <contact_backup>
      <last_name>Stephanie Ladd</last_name>
      <phone>203-737-8358</phone>
      <email>stephanie.ladd@yale.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Malesa Pereira</last_name>
      <phone>813-745-4090</phone>
      <email>malesa.pereira@moffitt.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute of Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Hutchison-Rzepka</last_name>
      <phone>404-778-3935</phone>
      <email>ahutch7@emory.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Georgia Cancer Center at Augusta University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosemary Chandler, BSN,RN,OCN</last_name>
      <phone>706-721-0730</phone>
      <email>mailto:rchandler@augusta.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grace Triska</last_name>
      <phone>314-747-4193</phone>
      <email>gracetriska@wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Franks</last_name>
      <phone>503-494-9324</phone>
      <email>frankse@ohsu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Bethany Wollam</last_name>
      <email>wollamb@ohsu.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Greenville Health System</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Johnson, RN</last_name>
      <phone>864-455-3600</phone>
      <email>ljohnson4@ghs.org</email>
    </contact>
    <contact_backup>
      <last_name>Jill Cantrell, RN</last_name>
      <phone>864-455-3600</phone>
      <email>jcantrell@ghs.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Pena, CCRP</last_name>
      <phone>801-213-4233</phone>
      <email>karen.pena@hci.utah.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwest Medical Specialties</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debi Kadoun</last_name>
      <phone>253-428-8752</phone>
      <email>dkadoun@nwmsonline.com</email>
    </contact>
    <contact_backup>
      <last_name>Linda Dhaene</last_name>
      <phone>253-428-8753</phone>
      <email>ldhaene@nwmsonline.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes - Hopital Pontchailou</name>
      <address>
        <city>Rennes</city>
        <state>Bretagne</state>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Rochas, MD</last_name>
      <phone>+33299289810</phone>
      <email>sophie.rochas@chu-rennes.fr</email>
    </contact>
    <contact_backup>
      <last_name>Nolwenn Boissel</last_name>
      <phone>+33299289201</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Clinica Universitaria de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Usua Montes</last_name>
      <phone>+34948255400</phone>
      <email>umontes@unav.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica de Rueda</last_name>
      <phone>+34935537120</phone>
      <email>mderueda@santpau.cat</email>
    </contact>
    <contact_backup>
      <last_name>Silvia Borrell</last_name>
      <phone>+34935537142</phone>
      <email>sborrell@santpau.cat</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabel Araujo</last_name>
      <phone>+34955926578</phone>
      <email>isabelaraujo.oncomacarena@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Esteban Nogales Fernandez, MD</last_name>
      <phone>+34955008932</phone>
      <email>esteban.nogales@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clare Day, MD</last_name>
      <phone>+01619187516</phone>
      <email>clare.day@christie.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Joanna Dash, MD</last_name>
      <phone>+4401619187226</phone>
      <email>joanna.dash@christie.nhs.uk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital</name>
      <address>
        <city>Surrey</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacqueline Oates</last_name>
      <phone>+442086613279</phone>
      <email>jacqui.oates@rmh.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Julie Duncan</last_name>
      <phone>+442086426011</phone>
      <email>julie.duncan@rmh.nhs.uk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>February 28, 2017</lastchanged_date>
  <firstreceived_date>July 8, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>follicular lymphoma</keyword>
  <keyword>fNHL</keyword>
  <keyword>low-grade lymphoma</keyword>
  <keyword>Non-Hodgkin's Lymphoma</keyword>
  <keyword>follicular NHL</keyword>
  <keyword>Marginal Zone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
